Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01400477 · ClinicalTrials.gov registry record · Phase 2
Nicotinic Receptors and Schizophrenia
A Phase 2 study of Schizophrenia and Schizoaffective Disorder, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 2
- Study locations
NCT01400477 is a Phase 2 study of Schizophrenia and Schizoaffective Disorder that has completed, run by University of Colorado, Denver. The registered enrollment target is 97 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01400477, a Phase 2 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia who are smokers and who are non-smokers. The study drug may also maintain abstinence from cigarette smoking and improve other symptoms in patients with schizophrenia.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG DMXB-A-SR
Study Locations (2)
Colorado
- UColorado Denver - Aurora
- University of Colorado-Anschutz Medical Campus, Department of Psychiatry - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01400477
The ClinicalTrials.gov registry entry for NCT01400477 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (56% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01400477 reports 2 study locations spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT01400477 about?
NCT01400477 is a clinical study titled "Nicotinic Receptors and Schizophrenia". The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia who are smokers and who are non-smokers. The study drug may also maintain abstinence from cigarette s...
What is the current status of trial NCT01400477?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2011-07. Estimated completion is 2015-06.
What conditions does trial NCT01400477 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT01400477?
The interventions under investigation include: Placebo (OTHER), DMXB-A-SR (DRUG).
Who is sponsoring clinical trial NCT01400477?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01400477 being conducted?
This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.